Synergistic anticancer effects of everolimus (RAD001) and Rhein on gastric cancer cells via phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway
Viability assay
Everolimus
DOI:
10.1080/21655979.2021.2005988
Publication Date:
2022-02-25T09:15:04Z
AUTHORS (8)
ABSTRACT
Everolimus (RAD001) is a mTOR inhibitor and widely used for the treatment of gastric cancer (GC). Evidence suggests that Rhein has anticancer effect on GC. But synergistic mechanism RAD001 combination GC not clear. The current study aims to clarify in treatment. We found dose-dependently repressed MGC-803 cell viability (50% inhibition concentration (IC50) value = 94.26 μM). (80 μM) significantly suppressed proliferation invasion. cells (IC50 45.41 nM). viability, invasion, compared administration or alone. Protein levels epithelial-mesenchymal transition (EMT)-related molecules E-cadherin, N-cadherin Vimentin expressions were affected by RAD001. facilitated apoptosis up-regulated cycle-related protein p53, cyclin-dependent kinase 4 (CDK4) cyclin D1 Moreover, phosphorylation-phosphoinositide-3-kinase (p-PI3K), p-protein B (p-AKT) p-mammalian target rapamycin (p-mTOR). Finally, decreased tumor weight volume, p-PI3K, p-Akt p-mTOR, marker Ki-67 expression, which exerted prevention
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (48)
CITATIONS (14)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....